Acute Kidney Injury (AKI) Market Insight, Epidemiology and Market Forecast Report 2021-2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Acute Kidney Injury (AKI) – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This ‘Acute Kidney Injury – Market Insights, Epidemiology and Market Forecast- 2030’ report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan.
Acute Kidney Injury Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI, and Age-specific Incident Population of AKI in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Key Findings
In 2020, the incident population of AKI in the 7MM was 10,907,615. The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.
- The United States encompasses the highest incident population of AKI in hospitalized patients, compared to EU5 and Japan. In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.
- In 2020, in the United States, there were 1,584,114, 401,606, and 245,426 cases of stage I, stage II, and stage III AKI respectively.
- In the US, the age group of 60-84 accounted for the highest cases in 2020, followed by 85+ years. In contrast, the least cases were found in the age group of 18-59. In 2020, there were 312,361, 1,004,016, and 914,770 cases, for the age groups 18-59 years, 60-84 years, and 85+ years, respectively.
- Epidemiology assessed for AKI showed that Germany accounted for the highest mortality-adjusted incident population of AKI in hospitalized patients in EU5, followed by the UK in 2020. The number of total mortality adjusted incidence of AKI in hospitalized patients is anticipated to be 906,731, 544,235, 506,725, 235,769 and 796,443 in 2020, for Germany, France, Italy, Spain, and UK, respectively.
- Epidemiology assessed for AKI showed that Japan, in 2020, accounted for the second-highest mortality-adjusted incident population of AKI in hospitalized patients in 7MM, about 1,323,519 cases.
Acute Kidney Injury Market Outlook
Key Findings
- The total market size is calculated by including the market size of both emerging and current therapies. The total market size in the 7MM for AKI was estimated to be USD 5,436 million in 2020 during the study period 2018-2030.
- In the 7MM, most of the share in the current market was captured by the United States, which was USD 2,786.7 million, while the second-highest revenue generator was Japan, taking nearly USD 840.4 million in its box, in 2020. The dynamics are anticipated to change during the forecast period, i.e., 2021-2030, owing to the launch of more effective drugs with clinically improved outcomes.
- Among the 7MM countries, the US accounts for the largest market size for AKI. The growth of market size for AKI is attributed to emerging therapies. The market size for AKI was USD 2,786.7 million in 2020.
- Among the EU-5 countries, Germany accounted for the highest market size of AKI in 2020. The market size of AKI in the EU5 was USD 1,809 million in 2020, inclusive of current treatment regimens. The lowest market is estimated to be covered by Spain, which accounts for USD 142.6 million in 2020.
- The market size for AKI in Japan was calculated to be USD 840.4 million in 2020.
Analyst Comments
- Since AKI is associated with multiple critical care complications such as cardiac surgery, DGF, sepsis, and many more, no targeted pharmacotherapies have been approved for AKI treatment. Consequently, the treatment solely depends on the existing off-label therapeutic options, such as diuretics, NSAIDs, RRT, etc., which have been used for decades.
- As there is no therapeutic cure to the disease, the risk of AKI is usually prevented by identifying patients at risk, reviewing medications, and reducing the exposure of patients to nephrotoxic drugs. The current treatment approach for such patients needs to be on the preventive side rather than on the curative side. Therefore, the emerging drugs such as bRESCAP, ANG-3777 for AKI-associated with cardiac surgery, QPI-1002, and Ruconest (Conestat alfa) are aiming to prevent the risk of AKI rather than providing therapeutic support after the cause of AKI.
- Amongst upcoming emerging therapies, ANG-3777 and teprasiran (QPI-1002) for DGF indication are expected to get approval earlier than AKI-associated with cardiac surgery. ANG-3777 has received the Fast Track and Orphan Drug designation by the US FDA and is planning to submit NDA by 2022 for DGF. QPI-1002, on the other hand, has been granted Orphan Drug designation by the US FDA and EU and is aiming to support NDA submission for the DGF indication. Besides, recAP and bRESCAP are also among the key players in the late phases of development and are expected to enter the market soon.
Companies Mentioned
- Alloksys
- Angion Biomedica
- Quark Pharmaceuticals
- AM Pharma
- Astellas Pharma
- Pharming Technologies
- Exponential Biotherapies
- Atox Bio
For more information about this report visit https://www.researchandmarkets.com/r/vk60zm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
